Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Integra gets US approval for next-gen dural graft:

This article was originally published in Clinica

Executive Summary

Integra NeuroSciences - a division of Integra LifeSciences Holdings - has received 510(k) clearance from the US FDA for its DuraGen XS dural regeneration matrix. The graft, for the sutureless closure of defects in the dura mater, has a higher collagen content while maintaining the same porous structure as Integra's previous generation materials, said the Plainsboro, New Jersey firm. Integra estimates that the graft has the potential to be used in around 225,000 neurosurgical procedures a year in the US. The dura mater is a tough fibrous membrane that surrounds and protects the brain and spinal cord. Head and spinal injuries, as well as neurosurgical procedures, can result in the rupture of the membrane, which must then be resealed in order to prevent the leaking of cerebrospinal fluid and to facilitate wound healing.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049737

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel